Information Provided By:
Fly News Breaks for December 11, 2019
Dec 11, 2019 | 11:46 EDT
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $80 price target on Arrowhead Pharmaceuticals (ARWR) following the company's submission of an IND for ARO-HIF2, with a Phase Ib dose escalation study in advanced clear cell renal cell carcinoma beginning pending review. The analyst added that Arrowhead also intends to initiate three pivotal Phase III trials in 2020, with the Phase II/III SEQUOIA trial of ARO-AAT to treat alpha-1 antitrypsin deficiency underway, ARO-APOC3 and ARO-ANG3 advancing into two Phase III cardiovascular trials in 2020, and Janssen conducting the Phase IIb REEF-1 combination study with ARO-HBV.
News For ARWR From the Last 2 Days
There are no results for your query ARWR